ArticleJournal of pharmaceutical policy and practice2025
A retrospective study on prevalence, characteristics, and outcomes of transcribing error: analysis of data from the National Medication Error Reporting System in Malaysia.
Article in Journal of pharmaceutical policy and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medication Errors Reporting and Analysis:Saudi medical journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medication errors (MEs) represent avoidable harm that occurs within the healthcare system. While most MEs do not pose significant safety threats, some can result in severe harm, disability, or even death for patients. We aimed to describe the prevalence, characteristics, and outcomes of MEs due to transcribing errors. Methods: Retrospective analysis of data from the Medication Error Reporting System (MERS) in Malaysia. All ME reports submitted to MERS were verified and classified by trained pharmacists from the Ministry of Health Malaysia. Transcribing errors were identified from all ME reports submitted to MERS that were classified as 'data entry error'. All data from public health facilities (hospitals and clinics) submitted in 2018-2022 were included in the analysis. Descriptive analyses were conducted on frequencies and characteristics of the transcribing errors. Results: From January 2018 to December 2022, 265,194 MEs were reported to the MERS, of which 12,049 (4.5%) were transcribing errors. The large proportion of transcribing error was related to dose error, i.e. incorrect dose (48.6%) and incorrect frequency (19.9%), followed by drug error (incorrect drug, 13.3% and incorrect patient, 6.3%). The majority of the errors do not reach patients (94.8%). The most possible error causes and contributing factors were work and environment followed by staff factors, task and technology, and medication-related. Conclusion: There was an increase in voluntary reporting over the years, reflecting a growing culture of reporting among healthcare professionals. These findings offer valuable insights into medication errors caused by transcribing processes in Malaysia, which can inform efforts to improve pharmacy practices, design appropriate interventions, and reduce harm to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.